Transgene

Transgene Operating Expenses

The Total Operating Expenses of Transgene (TNG.PA) as of Nov 18, 2026 is 41.74 M EUR. In the previous year, Total Operating Expenses was 37.65 M EUR — a change of 10.86% (higher).

Operating Expenses

41.74 MEUR

YoY

10.86%

Last updated:

Total Operating Expenses of Transgene is 2024 41.74 M EUR. Total Operating Expenses of Transgene was 2023 37.65 M EUR. It decreases by 10.86% higher compared to the previous year.

The Transgene Operating Expenses history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Operating Expenses
Date
Operating Expenses
Jan 1, 2017
35.44 M EUR
Jan 1, 2018
-304,000.00 EUR
Jan 1, 2019
38.69 M EUR
Jan 1, 2020
33.34 M EUR
Jan 1, 2021
40.54 M EUR
Jan 1, 2022
39.90 M EUR
Jan 1, 2023
37.65 M EUR
Jan 1, 2024
41.74 M EUR
The Transgene Operating Expenses history
YEAROperating ExpensesYoY
41.74 MEUR+10.86%
37.65 MEUR-5.65%
39.90 MEUR-1.57%
40.54 MEUR+21.60%
33.34 MEUR-13.84%
38.69 MEUR-12,827.30%
-304,000.00EUR-100.86%
35.44 MEUR+13.79%
31.15 MEUR-17.65%
37.83 MEUR-16.94%
45.54 MEUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Transgene Stock analysis

What does Transgene do? Transgene SA is a French biotechnology company specializing in the development and production of therapeutics, with a focus on cancer medications. It has a strong patent portfolio in the field of viral vectors, which are used for targeted gene therapy. The company's main areas of operation are clinical trials, research, and production. Transgene has research and production facilities in Strasbourg and Lyon, with over 100 employees. It has established partnerships with pharmaceutical companies, including Takeda Pharmaceuticals, for the development and marketing of therapeutics. Its flagship product, OncoVir-1®, is an immunomodulator that stimulates the immune system to fight tumor cells. Another promising product is TG4010, a therapeutic vaccine for non-small cell lung carcinoma. Transgene is an emerging company with a promising portfolio of cancer therapeutics, leveraging its expertise in viral vectors and collaborating closely with industry partners to expedite the development of marketable products. Transgene is expected to play a significant role in the development of new and innovative cancer treatments. Transgene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Transgene stock

Total Operating Expenses of Transgene is 41.74 M EUR in 2024.

Total Operating Expenses of Transgene changed from 37.65 M EUR to 41.74 M EUR, representing a 10.86% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Total Operating Expenses Transgene since 2006 – with annual values, charts, and detailed analysis.

Operating expenses are the costs incurred in the normal course of business operations, including COGS, SG&A, R&D, and depreciation.

Total Operating Expenses's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Total Operating Expenses's Transgene historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Transgene

All Key Metrics — Transgene